Treatment of non-functioning pituitary adenoma with cabergoline: a systematic review and meta-analysis

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorUniversidade Estadual Paulista (UNESP)-
Autor(es): dc.contributorUniversidade de São Paulo (USP)-
Autor(es): dc.contributorUniv Fed Parana-
Autor(es): dc.creatorBotelho, Mayra Souza-
Autor(es): dc.creatorFranzini, Italo Antunes-
Autor(es): dc.creatorNunes-Nogueira, Vania dos Santos-
Autor(es): dc.creatorBoguszewski, Cesar Luiz-
Data de aceite: dc.date.accessioned2025-08-21T18:32:43Z-
Data de disponibilização: dc.date.available2025-08-21T18:32:43Z-
Data de envio: dc.date.issued2022-11-29-
Data de envio: dc.date.issued2022-11-29-
Data de envio: dc.date.issued2022-07-28-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.1007/s11102-022-01257-5-
Fonte completa do material: dc.identifierhttp://hdl.handle.net/11449/237795-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/237795-
Descrição: dc.descriptionPurpose To make a systematic review and meta-analysis of studies evaluating the effect of cabergoline (CBG) in the treatment of non-functioning pituitary adenomas (NFPAs). Methods The primary outcome was tumor shrinkage, using as cut-off a reduction of at least 20% of the NFPA size from baseline. The secondary outcomes were prevention of tumor progression, clinically required additional interventions and adverse events (AE). Search strategies were applied to MEDLINE, EMBASE, LILACS and CENTRAL. Independent reviewers assessed the study eligibility, extracted data, and evaluated risk of bias. Random meta-analysis for the proportion of tumor shrinkage, prevention of tumor progression, clinically required additional interventions and frequency of AE were conducted. Results Five studies were included. The meta-analysis of proportion was 19% for tumor shrinkage (95% CI 8-38%, 4 studies, 108 participants), 50% for prevention of tumor progression (95% CI 35-64%, 5 studies, 187 participants), 14% for clinically required additional interventions (95% CI 6-30%, 4 studies, 128 participants) and 2% for adverse events (95% CI 1-6%, 3 studies, 157 participants). Conclusions Effect of CBG to promote tumor shrinkage in NFPAs was low, while prevention of tumor progression after surgery was seen in half of the cases, with a low frequency of adverse events. Systematic review registration PROSPERO CRD42020206778.-
Descrição: dc.descriptionSao Paulo State Univ, Med Sch, Dept Internal Med, UNESP, Ave Prof Mario Rubens Guimaraes Montenegro S-N, BR-18618687 Botucatu, SP, Brazil-
Descrição: dc.descriptionUniv Sao Paulo, Hosp Clin, Dept Internal Med, Fac Med,Univ Sao Paulo HCFMUSP, Sao Paulo, Brazil-
Descrição: dc.descriptionUniv Fed Parana, Dept Internal Med, Endocrine Div, SEMPR, Curitiba, Parana, Brazil-
Descrição: dc.descriptionSao Paulo State Univ, Med Sch, Dept Internal Med, UNESP, Ave Prof Mario Rubens Guimaraes Montenegro S-N, BR-18618687 Botucatu, SP, Brazil-
Formato: dc.format9-
Idioma: dc.languageen-
Publicador: dc.publisherSpringer-
Relação: dc.relationPituitary-
???dc.source???: dc.sourceWeb of Science-
Palavras-chave: dc.subjectCabergoline-
Palavras-chave: dc.subjectDopamine agonists-
Palavras-chave: dc.subjectPituitary neoplasms-
Palavras-chave: dc.subjectNon-functioning pituitary adenoma-
Palavras-chave: dc.subjectSystematic review-
Título: dc.titleTreatment of non-functioning pituitary adenoma with cabergoline: a systematic review and meta-analysis-
Tipo de arquivo: dc.typevídeo-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.